Tekmira Pharmaceuticals Corporation

Tekmira Pharmaceuticals Corporation
Name	Tekmira Pharmaceuticals Corporation
Former names	Protiva Biotherapeutics
Type	Public
Industry	Biotechnology
Founded	2006
Headquarters	Vancouver, British Columbia, Canada
Key people	Mark J. Murray; Thomas Madden
Products	Lipid nanoparticle delivery platforms; investigational therapeutics
Revenue	(historical; variable)

Tekmira Pharmaceuticals Corporation was a biotechnology company focused on RNA interference delivery and lipid nanoparticle technologies that operated primarily from Vancouver, British Columbia. The company developed delivery platforms and investigational therapeutics while engaging with pharmaceutical partners, investors, regulatory agencies, and academic collaborators across North America, Europe, and Asia. Tekmira interacted with entities such as Alnylam Pharmaceuticals, Arbutus Biopharma, Novartis, GlaxoSmithKline, and regulatory bodies like Health Canada and the United States Food and Drug Administration.

History

Tekmira originated from assets and personnel associated with Protiva Biotherapeutics and traces roots to scientific work linked to researchers at institutions like the University of British Columbia and corporate relationships with Inex Pharmaceuticals. Early corporate actions involved financing rounds with investors including venture firms comparable to ARCH Venture Partners and interactions with public markets such as the Toronto Stock Exchange and NASDAQ. The firm's history includes collaborations and disputes with companies including Alnylam Pharmaceuticals over delivery technologies and licensing, and a strategic reorganization that led to corporate actions involving Arbutus Biopharma and spin-out activity. Key moments involved litigation in Canadian and American courts, regulatory submissions to Health Canada and the United States Food and Drug Administration, and business development agreements with multinational pharmaceutical companies like Novartis and GlaxoSmithKline. Leadership during its operational period engaged with boards containing executives experienced at companies such as Pfizer, Merck & Co., Bristol-Myers Squibb, and Genentech.

Corporate Structure and Governance

Tekmira maintained a board of directors and executive team with backgrounds at organizations including Amgen, Eli Lilly and Company, Roche, and Johnson & Johnson. Governance practices reflected interactions with stock exchanges such as the Toronto Stock Exchange and NASDAQ, reporting to institutional investors similar to BlackRock, Vanguard Group, and biotechnology-focused venture investors like Third Rock Ventures. Corporate governance events included shareholder meetings, proxy contests, and strategic motions involving advisors from law firms with experience in biotechnology disputes comparable to those handled by Skadden, Arps, Slate, Meagher & Flom and DLA Piper. The firm’s corporate actions were influenced by Canadian corporate statutes and securities regulators such as the Canadian Securities Administrators and the Securities and Exchange Commission.

Research and Development

Tekmira’s R&D centered on lipid nanoparticle (LNP) delivery systems and RNA interference (RNAi) therapeutics, building on foundational science from laboratories associated with the University of British Columbia, MIT, and research groups led by scientists linked to Alnylam Pharmaceuticals and Sirna Therapeutics. Preclinical and clinical programs were conducted in collaboration with contract research organizations and academic medical centers, including protocols overseen by institutional review boards at hospitals comparable to Massachusetts General Hospital and universities such as Harvard University and Johns Hopkins University. R&D pipelines targeted infectious diseases, oncology, and rare genetic disorders, with translational efforts influenced by regulatory guidance from the United States Food and Drug Administration and European Medicines Agency. Scientific publications and conference presentations were delivered at venues like the American Society of Clinical Oncology and the American Association for the Advancement of Science.

Products and Pipeline

Tekmira developed and licensed lipid nanoparticle platforms used to formulate small interfering RNA and other nucleic acid therapeutics; these platforms were applied in investigational candidates targeting diseases studied by companies such as Alnylam Pharmaceuticals, Novartis, and GlaxoSmithKline. Pipeline assets included preclinical and early-stage clinical candidates for viral infections, oncology indications, and genetic conditions, with development milestones aligned to clinical trial registries overseen by entities like ClinicalTrials.gov. Collaborations produced co-development programs and out-licensing transactions with pharmaceutical partners and biotechnology firms similar to Sanofi and Roche. The company’s technology underpinned delivery systems later referenced in broader commercial successes in the RNA therapeutics field involving firms like Moderna and BioNTech.

Intellectual Property and Legal Matters

Tekmira maintained patent portfolios and licensing arrangements related to lipid nanoparticle formulations, manufacturing processes, and therapeutic applications, engaging with intellectual property counsel experienced with patent offices including the United States Patent and Trademark Office and the Canadian Intellectual Property Office. The company was party to high-profile legal disputes and licensing negotiations with firms such as Alnylam Pharmaceuticals and saw litigation that involved contract law and patent claims adjudicated in Canadian and U.S. courts. These matters affected strategic options, partnerships, and valuation discussions involving investment banks and legal advisors with experience in pharmaceutical disputes akin to those handled by firms like Skadden, Arps, Slate, Meagher & Flom and Covington & Burling.

Financial Performance and Partnerships

Tekmira financed operations through public offerings, private placements, and collaboration agreements with partners including Novartis, GlaxoSmithKline, and other multinational pharmaceutical companies; financing involved interactions with investment banks comparable to Goldman Sachs, Morgan Stanley, and RBC Capital Markets. Revenue streams included milestone payments, research funding, and licensing fees from strategic partnerships, while expenses reflected R&D, manufacturing, and legal costs reported to securities regulators such as the Securities and Exchange Commission and the Canadian Securities Administrators. The company’s financial performance influenced deals and alliances with biotechnology investors, strategic acquirers, and spin-out entities like Arbutus Biopharma, affecting shareholder value and capital markets activity on exchanges such as the Toronto Stock Exchange and NASDAQ.

Category:Biotechnology companies of Canada